Verbatim response from Perplexity
Zepbound costs approximately $1,060 to $1,349 per month without insurance depending on dosage, and single-dose vials are not cheaper than pens—they actually cost the same as single-dose pens, while KwikPens (multi-dose) are significantly cheaper at about $599.72/month for the 2.5 mg dose.
Monthly Cost Without Insurance
- The list price for Zepbound without coverage ranges from $1,060 to $1,349 per month based on dosage strength prescribed [1].
- Without discount cards or the Lilly Direct program, most patients pay over $1,000 per month [1].
- As of January 2026, the manufacturer list price for a 28-day supply ranges from $499 to $1,086, though actual pharmacy costs often exceed this [2].
- Starting in late 2025, Eli Lilly cut prices for its self-pay program: starter dose to $349/month, larger doses to $499/month [6].
Vials vs. Pens: Cost Comparison
| Dosage Form | Average Monthly Cost (2.5 mg, no insurance) |
|---|---|
| Single-dose pens | $1,291.31 |
| Single-dose vials | $1,291.31 (same as single-dose pens) |
| Zepbound KwikPens | $599.72 (nearly 50% cheaper) |
- Single-dose vials cost the same as single-dose pens ($1,291.31), so they are not cheaper than pens [2].
- The KwikPen (multi-dose monthly pen) is the cheapest option without insurance, costing about $599.72 for 2.5 mg [2].
- Through LillyDirect Self Pay Pharmacy, you can access KwikPens or vials starting at:
- $299 (2.5 mg), $399 (5 mg), $499 (7.5 mg), $699 (10–15 mg) per month [2][3].
- A promotional offer through December 2026 lowers 7.5–15 mg KwikPens or vials to $449/month [7].
Bottom Line
- Without insurance, expect to pay $1,000–$1,349/month for standard pens/vials.
- Vials are not cheaper than single-dose pens—they cost the same.
- To save significantly, choose the KwikPen or use LillyDirect’s self-pay program, which can reduce costs to $299–$449/month depending on dosage.
For best value without insurance, request the KwikPen or vial under LillyDirect’s self-pay offer rather than paying full pharmacy retail prices.